AD Pipeline Watch: Inmagene’s Anti-OX40 Monoclonal Antibody Performs Well in Phase 2a AD Trial
Treatment with Inmagene Biopharmaceuticals’ anti-OX40 monoclonal antibodyled to “rapid, marked, and durable” improvements of skin signs in in a Phase 2a trial of patients with atopic dermatitis (AD) IMG-007 is a non-depleting anti-OX40 mAb, bioengineered to have a silenced antibody-dependent cellular cytotoxicity (ADCC) function and a prolonged half-life. The Phase 2a trial (NCT05984784) evaluates the […]